Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

dzetu Feb. 26 at 10:14 AM

$CAPR We don't remember investing in you.

0 · Reply

IEatBearsForBreakfast Feb. 26 at 9:45 AM

$CAPR Good morning Capricor family, let’s keep chugging along

0 · Reply

Lion0fWallSt Feb. 26 at 9:19 AM

$ATOS $CAPR $SRPT $TTD Poppy shorts it to buy $PLTR , we have acquired 8,600 shares.

1 · Reply

Rascal7777777 Feb. 26 at 8:28 AM

$SRPT $CAPR $ATOS everyone report this mf sick fuck. Rot In Hell.

1 · Reply

Lion0fWallSt Feb. 26 at 7:50 AM

$SRPT $CAPR $ATOS you guys invested in retarded boys

3 · Reply

DragonAlgo Feb. 26 at 7:21 AM

🐉 $CAPR CALL — DragonAlgo® Signal Contract: CAPR CALL Expiry: 2026-03-20 | Strike: $29.00 | Type: CALL Option Plan (premium): Entry: $2.80 Stop: $2.02 TP1: $3.64 TP2: $4.76 TP3: $6.72 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Stonksgoingup Feb. 26 at 6:22 AM

$CAPR 🧐

0 · Reply

BioResearcher Feb. 26 at 5:00 AM

$CPIX $LRMR $CAPR CPIX's drug: Ifetroban is currently under preclinic trial to treat Friedreich ataxia. (FA) 's heart disease. LRMR's drug is for Friedreich ataxia. (FA).

0 · Reply

CAPRuccino Feb. 26 at 3:36 AM

$CAPR

2 · Reply

Bejita Feb. 25 at 11:12 PM

$CAPR still no BLA news ? always at the limit

4 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 2 months ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 2 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 3 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 3 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 3 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 3 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 4 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 4 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 5 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 5 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 5 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 5 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 5 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 6 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 6 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 7 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 7 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 7 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 8 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 8 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 8 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

dzetu Feb. 26 at 10:14 AM

$CAPR We don't remember investing in you.

0 · Reply

IEatBearsForBreakfast Feb. 26 at 9:45 AM

$CAPR Good morning Capricor family, let’s keep chugging along

0 · Reply

Lion0fWallSt Feb. 26 at 9:19 AM

$ATOS $CAPR $SRPT $TTD Poppy shorts it to buy $PLTR , we have acquired 8,600 shares.

1 · Reply

Rascal7777777 Feb. 26 at 8:28 AM

$SRPT $CAPR $ATOS everyone report this mf sick fuck. Rot In Hell.

1 · Reply

Lion0fWallSt Feb. 26 at 7:50 AM

$SRPT $CAPR $ATOS you guys invested in retarded boys

3 · Reply

DragonAlgo Feb. 26 at 7:21 AM

0 · Reply

Stonksgoingup Feb. 26 at 6:22 AM

$CAPR 🧐

0 · Reply

BioResearcher Feb. 26 at 5:00 AM

$CPIX $LRMR $CAPR CPIX's drug: Ifetroban is currently under preclinic trial to treat Friedreich ataxia. (FA) 's heart disease. LRMR's drug is for Friedreich ataxia. (FA).

0 · Reply

CAPRuccino Feb. 26 at 3:36 AM

$CAPR

2 · Reply

Bejita Feb. 25 at 11:12 PM

$CAPR still no BLA news ? always at the limit

4 · Reply

Cote0924 Feb. 25 at 10:32 PM

$CAPR Doug announced on today’s ER call he is leaving in 2026. Long time coming. Probably helps Srpt.

1 · Reply

Martinsucks Feb. 25 at 10:03 PM

$CAPR this is down after hours as well? Wtf is fk is going on here.

1 · Reply

Groggok Feb. 25 at 9:52 PM

$CAPR Here are the gory details of the WSJ article. Sadly this FDA is just a political clown show

6 · Reply

aladdinscarpet Feb. 25 at 9:39 PM

$CAPR https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?st=P7AvEn&reflink=desktopwebshare_permalink

0 · Reply

BioResearcher Feb. 25 at 9:34 PM

$LRMR $CAPR $CPIX $SRPT Glad I found LRMR, another hidden gem like CPIX, early!

0 · Reply

Cote0924 Feb. 25 at 9:20 PM

$CAPR Things still looking bleak over at Srpt https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025

0 · Reply

Cote0924 Feb. 25 at 9:13 PM

$CAPR WSJ really going after Vinay. Sorry it’s behind a paywall. https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?mod=e2two

0 · Reply